Revvity, Inc. vs. 10x Genomics, Inc. Class A Common Stock
Revvity, Inc. and 10x Genomics, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| RVTY | TXG | |
|---|---|---|
| Market Cap | $16.01 billion | $9.98 billion |
| Revenue (TTM) | — | $616.91 million |
| Net Income (TTM) | — | $-75,125,000 |
RVTY leads on 1 of 1 size & scale factors.
Valuation
| RVTY | TXG | |
|---|---|---|
| Price / Book | — | 12.09 |
| Price / Sales | — | 16.18 |
RVTY and TXG split the valuation factors evenly.
Profitability
| RVTY | TXG | |
|---|---|---|
| Net Margin | — | -12.18% |
| Return on Equity | — | -9.10% |
RVTY and TXG split the profitability factors evenly.
Dividend
| RVTY | TXG | |
|---|---|---|
| Dividend Yield | 0.20% | — |
RVTY and TXG split the dividend factors evenly.
Risk & Sentiment
| RVTY | TXG | |
|---|---|---|
| Short Interest | 2.98% | 0.42% |
TXG leads on 1 of 1 risk & sentiment factors.
Dig deeper: RVTY overview, RVTY financials, TXG overview, TXG financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.